West Pharmaceutical (WST) climbs as 2026 outlook and buyback support sentiment
West Pharmaceutical Services shares rose after the company posted strong fourth-quarter and full-year 2025 results and issued fiscal 2026 guidance calling for $3.215B–$3.275B in net sales and $7.85–$8.20 in adjusted EPS. Investors have also been focused on West’s newly authorized $1 billion share repurchase program and ongoing GLP-1/biologics-related demand momentum.
1) What’s moving the stock
West Pharmaceutical Services (WST) is trading higher as investors continue to reprice the company’s 2026 setup following its latest full-year results and forward outlook. West reported fourth-quarter net sales of $805.0 million and full-year 2025 net sales of $3.074 billion, alongside adjusted-diluted EPS of $2.04 for the quarter and $7.29 for the year, reinforcing a narrative of improving mix and momentum in higher-value components.
2) The key numbers investors are anchoring to
The company’s fiscal 2026 guidance calls for net sales of $3.215 billion to $3.275 billion and adjusted-diluted EPS of $7.85 to $8.20, with first-quarter 2026 guidance of $770 million to $790 million in net sales and $1.65 to $1.70 in adjusted-diluted EPS. West also highlighted strong High-Value Product (HVP) Components performance, including quarterly HVP Components net sales of $389.8 million (+20.3% reported), helping offset softer comparisons in delivery devices tied to a prior-year incentive fee.
3) Capital return and portfolio actions in focus
Sentiment has been supported by West’s capital return plans, including a newly authorized share repurchase program of up to $1 billion alongside its regular dividend. Investors are also tracking West’s portfolio repositioning, including the planned mid-2026 closing of the SmartDose 3.5mL on-body delivery system sale to AbbVie, which is explicitly incorporated into the company’s 2026 net sales outlook assumptions.
4) What to watch next
Near-term trading could hinge on any incremental updates about HVP Components demand (including GLP-1 and biologics exposure), the trajectory of margins as mix shifts, and confirmation that the SmartDose 3.5mL transaction closes on the expected timeline. Investors will also watch the cadence of buyback execution and whether West’s first-quarter results track above the current guidance range.